The Potential Clinical Utility of Circulating Tumor DNA in Esophageal Adenocarcinoma: From Early Detection to Therapy

Overview

Journal Front Oncol

Specialty Oncology

Date 2019 Jan 9

PMID 30619750

Citations 4

Authors

Juliann E Kosovec

Ali H Zaidi

Tamar S Pounardjian

Blair A Jobe

Affiliations

Soon will be listed here.

Abstract

Esophageal adenocarcinoma (EAC) is a lethal cancer requiring improved screening strategies and treatment options due to poor detection methods, aggressive progression, and therapeutic resistance. Emerging circulating tumor DNA (ctDNA) technologies may offer a unique non-invasive strategy to better characterize the highly heterogeneous cancer and more clearly establish the genetic modulations leading to disease progression. The presented review describes the potential advantages of ctDNA methodologies as compared to current clinical strategies to improve clinical detection, enhance disease surveillance, evaluate prognosis, and personalize treatment. Specifically, we describe the ctDNA-targetable genetic markers of prognostic significance to stratify patients into risk of progression from benign to malignant disease and potentially offer cost-effective screening of established cancer. We also describe the application of ctDNA to more effectively characterize the heterogeneity and particular mutagenic resistance mechanisms in real-time to improve prognosis and therapeutic monitoring strategies. Lastly, we discuss the inconsistent clinical responses to currently approved therapies for EAC and the role of ctDNA to explore the dynamic regulation of novel targeted and immunotherapies to personalize therapy and improve patient outcomes. Although there are clear limitations of ctDNA technologies for immediate clinical deployment, this review presents the prospective role of such applications to potentially overcome many of the notable hurdles to treating EAC patients. A deeper understanding of complex EAC tumor biology may result in the progress toward improved clinical outcomes.

Citing Articles

Advances in Screening for Barrett Esophagus and Esophageal Adenocarcinoma.

Vantanasiri K, Kamboj A, Kisiel J, Iyer P Mayo Clin Proc. 2024; 99(3):459-473.

PMID: 38276943 PMC: 10922282. DOI: 10.1016/j.mayocp.2023.07.014.

Case report: 16-yr life history and genomic evolution of an ER HER2 breast cancer.

Xu B, Amallraja A, Swaminathan P, Elsey R, Davis C, Theel S Cold Spring Harb Mol Case Stud. 2020; 6(6).

PMID: 33008833 PMC: 7784492. DOI: 10.1101/mcs.a005629.

Translational Application of Circulating DNA in Oncology: Review of the Last Decades Achievements.

Tuaeva N, Falzone L, Porozov Y, Nosyrev A, Trukhan V, Kovatsi L Cells. 2019; 8(10).

PMID: 31615102 PMC: 6829588. DOI: 10.3390/cells8101251.

Evolving Clinical Utility of Liquid Biopsy in Gastrointestinal Cancers.

Jacobson R, Munding E, Hayden D, Levy M, Kuzel T, Pappas S Cancers (Basel). 2019; 11(8).

PMID: 31412682 PMC: 6721625. DOI: 10.3390/cancers11081164.

References

Dressman D, Yan H, Traverso G, Kinzler K, Vogelstein B . Transforming single DNA molecules into fluorescent magnetic particles for detection and enumeration of genetic variations. Proc Natl Acad Sci U S A. 2003; 100(15):8817-22. PMC: 166396. DOI: 10.1073/pnas.1133470100. View

Tamoto E, Tada M, Murakawa K, Takada M, Shindo G, Teramoto K . Gene-expression profile changes correlated with tumor progression and lymph node metastasis in esophageal cancer. Clin Cancer Res. 2004; 10(11):3629-38. DOI: 10.1158/1078-0432.CCR-04-0048. View

Choi J, Reich 3rd C, Pisetsky D . The role of macrophages in the in vitro generation of extracellular DNA from apoptotic and necrotic cells. Immunology. 2005; 115(1):55-62. PMC: 1782131. DOI: 10.1111/j.1365-2567.2005.02130.x. View

Cunningham D, Allum W, Stenning S, Thompson J, van de Velde C, Nicolson M . Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006; 355(1):11-20. DOI: 10.1056/NEJMoa055531. View

Fleischhacker M, Schmidt B . Circulating nucleic acids (CNAs) and cancer--a survey. Biochim Biophys Acta. 2006; 1775(1):181-232. DOI: 10.1016/j.bbcan.2006.10.001. View

Diehl F, Schmidt K, Durkee K, Moore K, Goodman S, Shuber A . Analysis of mutations in DNA isolated from plasma and stool of colorectal cancer patients. Gastroenterology. 2008; 135(2):489-98. PMC: 2820386. DOI: 10.1053/j.gastro.2008.05.039. View

Koenig A, Prenzel K, Bogoevski D, Yekebas E, Bubenheim M, Faithova L . Strong impact of micrometastatic tumor cell load in patients with esophageal carcinoma. Ann Surg Oncol. 2008; 16(2):454-62. DOI: 10.1245/s10434-008-0169-7. View

Maher S, Gillham C, Duggan S, Smyth P, Miller N, Muldoon C . Gene expression analysis of diagnostic biopsies predicts pathological response to neoadjuvant chemoradiotherapy of esophageal cancer. Ann Surg. 2009; 250(5):729-37. DOI: 10.1097/SLA.0b013e3181bce7e1. View

Sikkema M, de Jonge P, Steyerberg E, Kuipers E . Risk of esophageal adenocarcinoma and mortality in patients with Barrett's esophagus: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2009; 8(3):235-44. DOI: 10.1016/j.cgh.2009.10.010. View

10.

Peters C, Rees J, Hardwick R, Hardwick J, Vowler S, Ong C . A 4-gene signature predicts survival of patients with resected adenocarcinoma of the esophagus, junction, and gastric cardia. Gastroenterology. 2010; 139(6):1995-2004.e15. DOI: 10.1053/j.gastro.2010.05.080. View

11.

Bang Y, Van Cutsem E, Feyereislova A, Chung H, Shen L, Sawaki A . Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010; 376(9742):687-97. DOI: 10.1016/S0140-6736(10)61121-X. View

12.

Motoori M, Takemasa I, Yamasaki M, Komori T, Takeno A, Miyata H . Prediction of the response to chemotherapy in advanced esophageal cancer by gene expression profiling of biopsy samples. Int J Oncol. 2010; 37(5):1113-20. DOI: 10.3892/ijo_00000763. View

13.

Kim S, Park Y, Park E, Cho J, Izzo J, Zhang D . Prognostic biomarkers for esophageal adenocarcinoma identified by analysis of tumor transcriptome. PLoS One. 2010; 5(11):e15074. PMC: 2994829. DOI: 10.1371/journal.pone.0015074. View

14.

Goh X, Rees J, Paterson A, Chin S, Marioni J, Save V . Integrative analysis of array-comparative genomic hybridisation and matched gene expression profiling data reveals novel genes with prognostic significance in oesophageal adenocarcinoma. Gut. 2011; 60(10):1317-26. DOI: 10.1136/gut.2010.234179. View

15.

Rao S, Welsh L, Cunningham D, te-Poele R, Benson M, Norman A . Correlation of overall survival with gene expression profiles in a prospective study of resectable esophageal cancer. Clin Colorectal Cancer. 2011; 10(1):48-56. DOI: 10.3816/CCC.2011.n.007. View

16.

Hvid-Jensen F, Pedersen L, Drewes A, Sorensen H, Funch-Jensen P . Incidence of adenocarcinoma among patients with Barrett's esophagus. N Engl J Med. 2011; 365(15):1375-83. DOI: 10.1056/NEJMoa1103042. View

17.

Higgins M, Jelovac D, Barnathan E, Blair B, Slater S, Powers P . Detection of tumor PIK3CA status in metastatic breast cancer using peripheral blood. Clin Cancer Res. 2012; 18(12):3462-9. PMC: 3533370. DOI: 10.1158/1078-0432.CCR-11-2696. View

18.

Pennathur A, Xi L, Litle V, Gooding W, Krasinskas A, Landreneau R . Gene expression profiles in esophageal adenocarcinoma predict survival after resection. J Thorac Cardiovasc Surg. 2013; 145(2):505-12. DOI: 10.1016/j.jtcvs.2012.10.031. View

19.

Chan K, Hung E, Woo J, Chan P, Leung S, Lai F . Early detection of nasopharyngeal carcinoma by plasma Epstein-Barr virus DNA analysis in a surveillance program. Cancer. 2013; 119(10):1838-44. DOI: 10.1002/cncr.28001. View

20.

Dulak A, Stojanov P, Peng S, Lawrence M, Fox C, Stewart C . Exome and whole-genome sequencing of esophageal adenocarcinoma identifies recurrent driver events and mutational complexity. Nat Genet. 2013; 45(5):478-86. PMC: 3678719. DOI: 10.1038/ng.2591. View